422
Participants
Start Date
June 3, 2021
Primary Completion Date
August 5, 2022
Study Completion Date
August 5, 2022
IMC-1
Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
Placebo BID Tablet
Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
IMC Study Site, Cedarhurst
IMC Study Site, Williamsville
IMC Study Site, Allentown
IMC Study Site, Charlottesville
IMC Study Site, Alpharetta
IMC Study Site, Jacksonville
IMC Study Site, Orlando
IMC Study Site, Tampa
IMC Study Site, Ocala
IMC Study Site, Oldsmar
IMC Study Site, Birmingham
IMC Study Site, Chattanooga
IMC Study Site, Knoxville
IMC Study Site, Jackson
IMC Study Site, North Canton
IMC Study Site, Cincinnati
IMC Study Site, Evansville
IMC Study Site, Des Moines
IMC Study Site, Gurnee
IMC Study SIte, Prairie Village
IMC Study Site, New Orleans
IMC Study Site, Covington
IMC Study Site, Prairieville
IMC Study Site, Rogers
IMC Study Site, Oklahoma City
IMC Study Site, Tulsa
IMC Study Site, Dallas
IMC Study Site, Austin
IMC Study Site, Salt Lake City
IMC Study Site, Albuquerque
IMC Study Site, Las Vegas
IMC Study Site, Oceanside
IMC Study Site, San Diego
IMC Study Site, Riverside
IMC Study Site, Temecula
IMC Study Site, Santa Ana
IMC Study Site, Sacramento
IMC Study Site, Portland
IMC Study Site, Everett
IMC Study Site, Boston
IMC Study Site, North Dartmouth
IMC Study Site, Warwick
Virios Therapeutics, Inc.
INDUSTRY